Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (4915)	11/9/2001 8:25:04 PM
From: keokalani'nui	Respond to of 52153

I too am interested in MI. And I will grant that if MI endpoints same as cabg, there could be trouble since there looks like little effect on lv function and perhaps would not expect much neurocog benefit with pci or thromboylsis. OTOH, more likely to see clinical effect with bolus only and and in cabg there was 24% reduction at ckmb>60, though not ss. Now that you get me thinking, it is also smart strategy even if bullish on drug, to wait. But neurcog improvement, if actually good, will mark at least a short term beginning. And those results come out 11/12. Wilder